Congresos 2023
En esta página podrá descargarse la información más relevante de Larotrectinib presentada en los congresos de 2023.
ASCO 2023
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. (Hong DS, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 3141).
Long-term efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. (Lin JJ, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 9056).
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). (Cabanillas ME, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 6091).
ESMO 2023
Larotrectinib Extended Data Set (A. Drilon, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S470.
Efficacy and safety of Larotrectinib as first-line treatment for patients with TRK fusion cancer (Hong DS, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S469).
CONNECTIVE TISSUE ONCOLOGY SOCIETY 2023
Updated efficacy and safety of Larotrectinib in adult patients with TRK fusion sarcomas (McDermott R, et al. Poster presentation at CTOS 2023:Abstract 1569432).
Efficacy, safety, and treatment hold wait-and-see outcomes of Larotrectinib in pediatric patients with TRK fusion sarcomas (Albert CM, et al. Poster presentation at CTOS 2023:Abstract 1570241).
INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY 2023
Comparison of clinical outcomes of patients with infantile fibrosarcoma treated with Larotrectinib in the SCOUT study versus historical cohort THE EPI-VITRAKVI STUDY (D. Orbach, et al.44O. ESMO Open, Volume 8, Issue 1, Supplement 3, 2023).
SOCIETY FOR NEUROONCOLOGY 2023
Efficacy and safety of Larotrectinib in patients with TRK fusion primary central nervous system tumors: An updated analysis (Perreault S, et al. Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v95).